



Abgenix to Present at BIO CEO & Investor Conference 2005

FREMONT, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Abgenix, Inc. (Nasdaq: ABGX) today announced that the company will present at BIO CEO & Investor Conference on Thursday, February 24, 2005 at 12:00 p.m. PT, 3:00 p.m. ET. The presentation will be webcast live and may be accessed by visiting the Abgenix website at www.abgenix.com. A replay of the webcast will also be available on the company's website until Thursday, March 10, 2005.

Bill Ringo, president and chief executive officer of Abgenix, will provide an update on the company's antibody drug development activities.

About Abgenix

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through its own development efforts and through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com.

SOURCE Abgenix, Inc.
02/18/2005

CONTACT: Ami Knoefler, Senior Director, Corporate Communications and Investor Relations, of Abgenix, Inc., +1-510-284-6350 or +1-510-284-6605/ Web site: <http://www.abgenix.com>